Presbyopia Drops

As we age, our eyes gradually lose the ability to clearly focus at near distances. This condition is known as presbyopia and an estimated 112 million Americans over age 40 are currently experiencing its effects.1

COMING IN 2020:  EyeFocus™ & EyeFocus+™ are intended for presbyopia. Both formulations were developed in partnership with FOV Tears creator Luis Felipe Vejarano, MD, and contain low concentrations of pilocarpine, phenylephrine, pheniramine and ketorolac.

 

Pilocarpine HCl 0.302%
Phenylephrine HCl 0.624%
Pheniramine 0.772%
Ketorolac 0.01%
Sterile Ophthalmic Solution 

9 mL

Pilocarpine HCl 0.604%
Phenylephrine HCl 0.624%
Pheniramine 0.772%
Ketorolac 0.01%
Sterile Ophthalmic Solution 

9 mL

"EyeFocus represents a paradigm-shift in how we approach presbyopia correction in the U.S. I believe patients will find the prospect of using a drop medication as a situational alternative to reading glasses not only exciting but also tremendously liberating. As such, I expect EyeFocus to be a significant practice differentiator for doctors who embrace this revolutionary treatment."
- LUIS FELIPE VEJARANO, MD, INVENTOR OF FOV TEARS

"I'm very excited to be able to offer this to my patients. Both my wife and I are presbyopic and cannot read without glasses. Within 20 minutes of instilling the drop, we were both able to take our glasses off and read."
- Robert Weinstock, MD, The Eye Institute of West Florida